Navigation Links
Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement

BRAINTREE, Mass., Dec. 14 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that it has filed a new legal action to stop Fenwal Inc.'s continued patent infringement resulting from Fenwal's just released red cell collection kits, using a modified separation chamber. Fenwal allegedly modified its separation chamber to circumvent Haemonetics' patent and the injunction entered by the Court prohibiting Fenwal's continued sale of infringing products after December 1, 2010. According to statements made by Fenwal's counsel today in the United States District Court, Fenwal is determined to proceed with commercialization without 510(k) clearance from the U.S. Food & Drug Administration.

On December 7, 2009 Fenwal announced that it began shipping a red cell collection kit with a modified separation chamber, and that it is discontinuing sales of its original kit. Ten months ago, on January 31, 2009, a federal jury had determined that Fenwal's original collection kit infringes a Haemonetics patent, and found Fenwal liable to Haemonetics for over $15 million in damages. The United States District Court for the District of Massachusetts later added millions of dollars in pre-judgment interest and ordered the product removed from the market by December 1, 2010. The District Court also ordered that between January 31, 2009 and December 1, 2010, Fenwal must pay Haemonetics a 10% royalty on the offending product's sales. The damages have not been paid, and the royalties are being escrowed pending decision on Fenwal's appeal to the United States Court of Appeals for the Federal Circuit. A decision by the appellate court is not expected before late 2010 at the earliest.

Haemonetics filed a new lawsuit against Fenwal on account of the modified collection kit, requesting another jury trial that seeks multiple damages for willful infringement, and a permanent injunction. The new matter has been assigned to the same federal judge who issued the permanent injunction on Fenwal's original red cell kit.

Brian Concannon, Haemonetics' President and CEO said, "We commit to supporting blood collectors who wish to assure an orderly transition away from infringing product well in advance of the December 2010 injunction. It is our genuine desire to protect customers from involvement in this commercial dispute between competitors. As we continue to make multi million dollar investments to bring new technologies and blood management offerings to the blood community, we are likewise committed to protect our intellectual property, which is the foundation of the business we've built."

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at .

    Julie Fallon
    Tel. (781) 356-9517
    Alternate Tel. (617) 320-2401

SOURCE Haemonetics Corporation

SOURCE Haemonetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Haemonetics Sets Date for Second Quarter Fiscal Year 2010 Earnings Release: November 2, 2009
2. Haemonetics Signs Comprehensive Agreement with Blood Centers of America
3. Haemonetics Expands Its Blood Management Product Portfolio with Acquisition of SEBRA Business Unit
4. Haemonetics Sets Date for First Quarter Fiscal Year 2010 Earnings Release: August 3, 2009
5. Haemonetics Shares Success of Outstanding Fiscal 2009 Performance with Employees
6. Haemonetics Sets Date For Fourth Quarter Fiscal Year 2009 Earnings Release: May 4, 2009
7. Haemonetics Sets Date for Investor/Analyst Meeting
8. Haemonetics Expands Its Blood Management Leadership With Acquisition of Neoteric Technology Ltd
9. Haemonetics Announces Change to Board of Directors
10. Haemonetics Bolsters Blood Bank Information Management Portfolio With Acquisition of Altivation Software
11. Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... Rehabilitation P.C.went to NASDAQ to educate the personnel on spinal decompression therapy and ... the spine, a nonsurgical procedure. The benefits come from creating negative intradiscal pressure ...
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition ... funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday ... from patients including their ability to work and be productive, to do simple daily ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... detailing the important role that meat and poultry play in a healthy, ... poultry, a nutrition quiz where visitors can check their “meat IQ,” a section ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... World ... the Multi Jar, a container patent that allows for easier packing and organizing of ... US is worth $90 billion," says Scott Cooper, CEO and Creative Director of World ...
(Date:12/1/2015)... ... 01, 2015 , ... Henderson, a town of about 6,300 ... through a partnership this year with Aeneas Internet and Telephone. , With faster ... for entrepreneurs who want to build a business. Whether startups or long established ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... and VANCOUVER , Dec. 1, 2015 ... OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today ... on the pre-planned interim futility analysis of the intent-to-treat ... safety issues were identified by the DMC. Both the ... final results are expected in the second half of ...
(Date:12/1/2015)... Dec. 1, 2015 As enforcement of the ... Security Act (DSCSA) approaches, InfiniTrak announced ... pharmacies comply with looming FDA regulations. ... entering endorsement agreements with State Pharmacy Associations, an ... organization (PSAO) to exclusively provide the InfiniTrak track-and-trace ...
(Date:12/1/2015)... 2015 ... "Medium Molecular Weight Polyisobutylene Market for ... Applications - Global Industry Analysis, Size, Share, ... report to their offering. --> ... of the "Medium Molecular Weight Polyisobutylene ...
Breaking Medicine Technology: